Hepatitis C infection among recent initiates to injecting in England 2000-2008: Is a national hepatitis C action plan making a difference?

Journal of Viral Hepatitis

Volumn 19, Issue 1, 2012, Pages 55-64

  Hope, V ^a,b   Parry, J V ^a,b   Marongui, A ^a   Ncube, F ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

hepatitis C; incidence; injecting drug use; prevalence; voluntary confidential testing

Indexed keywords

ADULT; ARTICLE; FEMALE; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NEEDLE; PREVALENCE; PRIORITY JOURNAL; PRISONER; STRUCTURED QUESTIONNAIRE; UNITED KINGDOM; VIRUS TRANSMISSION;

ADULT; DIAGNOSTIC TESTS, ROUTINE; ENGLAND; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; NATIONAL HEALTH PROGRAMS; QUESTIONNAIRES; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84255198857     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01415.x     Document Type: Article

References (46)

1. Alter MJ, Moyer LA,. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: S6-S10. (Pubitemid 28304462)
2. Roy K, Hay G, Andragetti R, et al. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 2002; 12: 577-585. (Pubitemid 36157682)
3. Hagan H, Pouget ER, Des Jarlais DC, et al. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008; 168: 1099-1109.
4. De Angelis D, Sweeting M, Ades AE, et al. An evidence synthesis approach to estimating hepatitis C prevalence in England and Wales. Stat Methods Med Res 2009; 18: 361-379.
5. Health Protection Agency, Health Protection Scotland, National Public Health Service for Wales, CDSC Northern Ireland, and CRDHB. Shooting Up: Infections among injecting drug users in the United Kingdom 2008. London: Health Protection Agency, October 2009. ISBN 978-0-901144-07-2
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
7. Tilson H, Aramrattana A, Bozzette SA, et al. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: Institute of Medicine, 2007.
8. Advisory Council on Misuse of Drugs. The Primary Prevention of Hepatitis C Among Injecting Drug Users. London: United Kingdom: Home Office, 2009
9. Hepatitis C Strategy for England. London: Department of Health, 2002.
10. Hepatitis C Action Plan for England. London: Department of Health, 2004.
11. Noone A, Durante AJ, Brady AR, et al. HIV infection in injecting drug users attending centres in England and Wales, 1990-1991. AIDS 1993; 7: 1501-1507. (Pubitemid 23333841)
12. Hope VD, Judd A, Hickman M, et al. HIV prevalence among injecting drug users in England & Wales 1990 to 2003: evidence for increased transmission in recent years. AIDS 2005; 19: 1207-1214. (Pubitemid 41059263)
13. Judd A, Parry J, Hickman M, et al. Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J Med Virol 2003; 71: 49-55. (Pubitemid 37121912)
14. Hepatitis C in the UK. London: Health Protection Agency Centre for Infections, December 2009.
15. Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005; 330: 24-25. (Pubitemid 40070473)
16. Hope VD, Hickman M, Ngui SL, et al. Measuring the incidence, prevalence, and genetic relatedness of hepatitis C infections among community recruited sample of injecting drug users using dried blood spots. J Viral Hepat, 2010 DOI: 10.1111/j.1365-2893.2010.01297.x.
17. Craine N, Hickman M, Parry JV, et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiol Infect 2009; 137: 1255-1265.
18. Roy K, Goldberg D, Taylor A, et al. A method to detect the incidence of hepatitis C infection among injecting drug users in Glasgow 1993-98. J Infect 2001; 43: 200-205. (Pubitemid 34211103)
19. Aarons E, Grant P, Soldan K, et al. Failure to diagnose recent hepatitis C virus infections in London injecting drug users. J Med Virol 2004; 73: 548-553. (Pubitemid 38857204)
20. Vickerman P, Hickman M, Judd A,. Modelling the impact on hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol 2007; 36: 396-405. (Pubitemid 47062861)
21. Vickerman P, Miners A, Williams J,. Assessing the Cost-Effectiveness of Interventions Linked to Needle and Syringe Programmes for Injecting Drug Users: An Economic Modelling Report. London School of Hygiene and Tropical Medicine, Bristol University & Imperial College. NICE, June 2008.
22. Van Den Berg C, Smit C, Van Brussel G, et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 1454-1462. (Pubitemid 47246988)
23. NTA. The NTA's 2006 National Prescribing Audit: An Assessment of Prescribing Practices for Opioid Substitution Treatment in England, 2004-05. London: NTA, April 2007.
24. Improving Services for Substance Misuse: Commissioning Drug Treatment and Harm Reduction Services. London, Healthcare Commission and National Treatment Agency, 2008. ISBN 978-1-84562-184-1
25. National Treatment Agency for Substance Misuse. Findings of a Survey of Needle Exchanges in England. London: NTA, May 2006. Research briefing:17.
26. Hickman M, Higgins V, Hope V, et al. Injecting drug use in Brighton, Liverpool, and London: best estimates of prevalence and coverage of public health indicators. J Epidemiol Community Health 2004; 58: 766-771. (Pubitemid 39127887)
27. Sweeting MJ, Hope VD, Hickman M, et al. Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again? Am J Epidemiol 2009; 170: 352-360.
28. Department of Health. The Health of the Nation: A Strategy for Health in England. London: The Stationery Office, 1992. ISBN: 0101198620
29. Central Drugs Coordination Unit. Tackling Drugs to Build a Better Britain: The Governments Ten-year Strategy for Tackling Drug Misuse. London: The Stationery Office, 1998.
30. Stimson GV,. 'Blair declares war': the unhealthy state of British drug policy. Int J Drug Policy 2000; 11: 259-264. (Pubitemid 30445051)
31. Update Drugs Strategy. London: Home Office, 2002. ISBN 1-84082-9397
32. Drugs: Protecting Families and Communities: The 2008 Drug Strategy. London: HM Government; COI. ISBN 978-1-84726-616-3.
33. De Angelis D, Hickman M, Yang S,. Estimating long-term trends in the incidence and prevalence of opiate/injecting drug use and the number of ex-users: the use of back-calculation methods and opiate overdose deaths. Am J Epidemiol 2004; 160: 994-1004. (Pubitemid 39488428)
34. Hope VD, Hickman M, Tilling K,. Capturing crack-cocaine use: estimating the prevalence of Crack-cocaine use in London using capture-recapture with covariates. Addiction 2005; 100: 1701-1708. (Pubitemid 41626830)
35. Location, Location, Location. An Audit of Hepatitis C Healthcare in England. An All-Party Parliamentary Hepatology Group Report. London: 14 February 2008.
36. Reducing Drug-related Harm: An Action Plan. London: Department of Health, 2007. 281030 1p 3k May 07 (CWP)
37. Good Practice in Harm Reduction. London: National Treatment Agency for Substance Misuse, October 2008.
38. Harm Reduction Works.
39. NICE. Needle and Syringe Programmes: Providing People Who Inject Drugs with Injecting Equipment. NICE, Public Health Guidance, PH18, February 2009.
40. NICE. Drug misuse-Methadone and Buprenorphine. NICE, Technology Appraisal, TA114, January 2007.
41. Hope VD, Ncube F, Hickman M, Judd A, Parry JV,. Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements? J Viral Hepat, 2007; 14: 653-660. (Pubitemid 47258268)
42. Hickman M, MacDonald T, Judd A, et al. Increasing the uptake of hepatitis C virus (HCV) testing: a cluster randomised controlled trial of the use of dried blood spots (DBS) for diagnostic testing of HCV among injecting drug users in prison and community settings. J Viral Hepat, 2008; 15: 250-254. (Pubitemid 351326904)
43. Hickman M, Hope V, Brady T, et al. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat 2007; 14 (9): 645-652. (Pubitemid 47258267)
44. De Irala J, Bigelow C, McCusker J, Hindin R, Zheng L,. Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. Am J Epidemiol 1996; 143: 725-732. (Pubitemid 26108239)
45. Latkin CA, Vlahov D, Anthony JC,. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction 1993; 88: 517-526.
46. English L,. Treatment and care for older drug users. In:, Eaton G, Davies C, English L, Lodwick A, Bellis MA, McVeigh J, eds. National report to the EMCDDA by the Reitox National Focal Point United Kingdom: New Developments, Trends and In-Depth Information on Selected Issues: 2009. 203-223. London: UK Focal Point on Drugs, 2009. ISBN 978-1-907441-06-6